Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern
- PMID: 3406919
- PMCID: PMC461220
- DOI: 10.1136/thx.43.4.318
Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern
Abstract
Antibiotic aerosol treatment is successful in treating Pseudomonas infection in some patients with cystic fibrosis, but the amount of drug reaching the lungs is unknown. The deposition patterns of carbenicillin aerosols delivered from two commercially available nebuliser systems (the Turret nebuliser plus Maxi compressor and the Inspiron nebuliser plus Traveller compressor) have been compared in six patients with cystic fibrosis during tidal breathing. The aerosol mass median diameters were 3.2 and 7.3 microns. In addition, the aerosol from the Turret-Maxi nebuliser system was inhaled by a combination of tidal and deep breathing. After two minutes' breathing via a mouthpiece the mean (SEM) deposition in the lungs was 15.60 (1.5) mg carbenicillin with the Turret nebuliser plus Maxi compressor, but only 6.54 (1.09) mg with the Inspiron nebuliser plus Traveller compressor; the distribution pattern within the lung was significantly more peripheral with the former nebuliser system. These differences may be ascribed partly to the smaller droplet size from the Turret system and partly to the higher nebulisation rate from the more powerful Maxi compressor. Tidal plus deep breathing produced a further small but non-significant increase in lung aerosol deposition. A seventh patient, who failed to complete the trial, had little aerosol deposited in his lungs because he inhaled through his nose. These results emphasise the importance of correct selection of nebuliser equipment for antibiotic aerosol treatment.
Similar articles
-
Choice of nebulisers and compressors for delivery of carbenicillin aerosol.Eur J Respir Dis. 1986 Sep;69(3):160-8. Eur J Respir Dis. 1986. PMID: 3780896
-
[Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer].Rev Mal Respir. 1996;13(1):55-60. Rev Mal Respir. 1996. PMID: 8650418 Clinical Trial. French.
-
Effect of nebulised aerosol size on lung deposition in patients with mild asthma.Thorax. 1987 Mar;42(3):190-4. doi: 10.1136/thx.42.3.190. Thorax. 1987. PMID: 3303427 Free PMC article. Clinical Trial.
-
[Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].Rev Pneumol Clin. 2002 Jun;58(3 Pt 1):131-8. Rev Pneumol Clin. 2002. PMID: 12486796 Review. French.
-
Inhaled antibiotics: dry or wet?Eur Respir J. 2014 Nov;44(5):1308-18. doi: 10.1183/09031936.00090314. Epub 2014 Oct 16. Eur Respir J. 2014. PMID: 25323242 Review.
Cited by
-
Hydrophilic and lipophilic radiopharmaceuticals as tracers in pharmaceutical development: in vitro--in vivo studies.BMC Nucl Med. 2005 Oct 18;5:5. doi: 10.1186/1471-2385-5-5. BMC Nucl Med. 2005. PMID: 16232323 Free PMC article.
-
Nebulised antibiotics for adults with cystic fibrosis.Thorax. 1997 Apr;52 Suppl 2(Suppl 2):S69-71. doi: 10.1136/thx.52.2008.s69. Thorax. 1997. PMID: 9155856 Free PMC article. No abstract available.
-
Pulmonary deposition of a nebulised aerosol during mechanical ventilation.Thorax. 1993 Feb;48(2):154-9. doi: 10.1136/thx.48.2.154. Thorax. 1993. PMID: 8493630 Free PMC article.
-
Nuclear medicine techniques in the evaluation of pharmaceutical formulations.Pharm World Sci. 1996 Jun;18(3):97-104. doi: 10.1007/BF00417757. Pharm World Sci. 1996. PMID: 8826534 Review.
-
Nebuliser systems for drug delivery in cystic fibrosis.Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3. Cochrane Database Syst Rev. 2023. PMID: 37942828 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical